Literature DB >> 20632005

Radio-guided excision of metastatic lymph nodes in thyroid carcinoma: a safe technique for previously operated neck compartments.

Yeşim Erbil1, Serkan Sari, Orhan Ağcaoğlu, Feyzullah Ersöz, Adem Bayraktar, Artür Salmaslioğlu, Osman Gozkun, Işik Adalet, Selçuk Ozarmağan.   

Abstract

BACKGROUND: Better follow-up of patients with papillary thyroid cancer (PTC) and more sensitive detection leads to detection of recurrences in the neck. Despite excellent outcomes, the major challenge is controlling locoregional recurrence. We aimed to investigate whether the radio-guided excision of metastatic lymph nodes makes it possible to find the affected lymph nodes in patients with previously operated neck compartments.
METHOD: This prospective study included 46 patients with recurrent/persistent PTC who had previously undergone operation of the neck compartment. Prior to operation, the pathologic node was localized by ultrasound (US) and radiotracer ((99m)Tc-labeled rhenium colloid) was injected directly into the pathologic node. Careful dissection was carried out following the area of maximum radioactivity until the metastatic lymph node(s) were identified and excised. RESULT: One affected lymph node was removed in 17 patients, and more than one lymph node (affected or additional nodes) was removed in 29 patients. The median count from the lesion was significantly higher than values from the lesion bed (background activity) (16,886 counts/20 s versus 52 counts/20 s; p < 0.001). During follow-up, four patients were lost to follow-up and 27 patients had negative US and basal thyroglobulin (Tg). Five patients had suspicious lymph nodes on the operated side. Although the basal Tg level remained above the normal limit, moderately high in 8 patients, no metastases were detected in the neck.
CONCLUSIONS: Radio-guided excision of metastatic lymph nodes can be performed safely for the detection and excision of recurrent thyroid cancer in the central and lateral neck.

Entities:  

Mesh:

Year:  2010        PMID: 20632005     DOI: 10.1007/s00268-010-0714-y

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  16 in total

Review 1.  Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; R T Kloos
Journal:  J Clin Endocrinol Metab       Date:  2001-04       Impact factor: 5.958

2.  Intraoperative ultrasonography improves identification of recurrent thyroid cancer.

Authors:  John K Karwowski; R Brooke Jeffrey; I Ross McDougall; Ronald J Weigel
Journal:  Surgery       Date:  2002-12       Impact factor: 3.982

3.  European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium.

Authors:  Furio Pacini; Martin Schlumberger; Henning Dralle; Rossella Elisei; Johannes W A Smit; Wilmar Wiersinga
Journal:  Eur J Endocrinol       Date:  2006-06       Impact factor: 6.664

4.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

5.  Hook needle-guided excision of recurrent differentiated thyroid cancer in previously operated neck compartments: a safe technique for small, nonpalpable recurrent disease.

Authors:  Frederic Triponez; Liina Poder; Rasa Zarnegar; Ruth Goldstein; Kayvan Roayaie; Vickie Feldstein; James Lee; Electron Kebebew; Quan-Yang Duh; Orlo H Clark
Journal:  J Clin Endocrinol Metab       Date:  2006-09-12       Impact factor: 5.958

6.  Occult breast lesions: A comparison between radioguided occult lesion localisation (ROLL) vs. wire-guided lumpectomy (WGL).

Authors:  R Nadeem; L S Chagla; O Harris; S Desmond; R Thind; C Titterrell; R A Audisio
Journal:  Breast       Date:  2005-08       Impact factor: 4.380

7.  Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma.

Authors:  Andrea Frasoldati; Marialaura Pesenti; Marco Gallo; Angelo Caroggio; Diana Salvo; Roberto Valcavi
Journal:  Cancer       Date:  2003-01-01       Impact factor: 6.860

8.  Central lymph node dissection as a secondary procedure for papillary thyroid cancer: Is there added morbidity?

Authors:  Raul Alvarado; Mark S Sywak; Leigh Delbridge; Stan B Sidhu
Journal:  Surgery       Date:  2009-03-27       Impact factor: 3.982

9.  Radio-guided nonpalpable metastatic lymph node localization in patients with recurrent thyroid cancer.

Authors:  Mustafa Tükenmez; Yeşim Erbil; Umut Barbaros; Cem Dural; Artür Salmaslioglu; Deniz Aksoy; Ayse Mudun; Selçuk Ozarmağan
Journal:  J Surg Oncol       Date:  2007-11-01       Impact factor: 3.454

10.  Radiofrequency ablation of regional recurrence from well-differentiated thyroid malignancy.

Authors:  D E Dupuy; J M Monchik; C Decrea; L Pisharodi
Journal:  Surgery       Date:  2001-12       Impact factor: 3.982

View more
  2 in total

Review 1.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

2.  Ultrasound dye-assisted surgery (USDAS): a promising diagnostic and therapeutic tool for the treatment of cancer recurrences in the neck.

Authors:  G Giugliano; E DE Fiori; M Proh; T Chulam Celestino; E Grosso; A Cattaneo; B Gibelli; M Massaro; M Ansarin
Journal:  Acta Otorhinolaryngol Ital       Date:  2011-08       Impact factor: 2.124

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.